Toyo Jozo Kabushiki Kaisha

Toyo Jozo Company, Ltd.

Asahi Kasei Kogyo Kabushiki Kaisha

Toyo Yozo Company, Ltd.

Tetsu Saito

Naoki Muto

Masaru Otani

Yukio Suzuki

Tadashiro Fujii

Satoshi Yaginuma

Shuzo Satoi

Masao Yaso

Eiichi Hayashi

Mitsuo Hayashi

Noriyasu Takayanagi

Masatoshi Tsujino

Kazuo Matsuura

Daisuke Mochizuki

Masaki Takada

Kensuke Shibata

Tetsuo Matsuda

Eiichi Honda

Takehiko Sasahara

Kenya Ishizawa

Junzo Mizoguchi

Takeo Higashino

Masaru Ono

Hiroyuki Kinoshita

Atsuki Morishita

Kimio Mizuno

Katsumi Asano

Akira Yagi

Minoru Toriya

Seiji Katsumata

Kenzi Saeki

Katumi Nisimura

Described herein are pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives represented by the following formula (I): ##STR1## wherein R.sub.1 and R.sub.2 individually mean a hydrogen atom or a lower alkyl group, R.sub.3 denotes an azabicyclo group containing a tertiary nitrogen atom, and Y stands for --O-- or --NH--, or salts thereof. Their preparation process and serotonin receptor antagonists containing them as active ingredients are also described.

Pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives and their

A antibiotic L53-18A and a pharmaceutically acceptable salt thereof which are useful for treatment of bacterial inventions are obtained by culturing, for example, Saccharopolyspora sp. L53-18 (FERM BP 2231) in a medium and the antibiotic accumulated therein is collected.

Antibiotic L53-18A and process for preparation thereof

A compound of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, R.sup.2 is hydrogen, lower alkoxy or halogen, and A is lower alkylene, or a pharmacologically acceptable salt thereof, has sympatholytic .alpha.-receptor blocking activity and is useful for the treatment of hypertension.

1-Substituted alkyl-2-oxo-1,2-dihydroquinoxaline derivatives

A compound of the formula ##STR1## wherein Z is N or NH,  is a single or double bond, R.sub.1 is hydrogen, C.sub.1-20 alkyl or optionally substituted phenyl, A is lower alkylene, R is carboxyl, lower alkoxycarbonyl, ##STR2## or 1-cycloalkyl-tetrazole-5-yl, R.sub.2 is lower alkyl, hydroxy-lower alkyl or optionally substituted phenyl-lower alkyl, R.sub.3 is lower alkyl or cycloalkyl, or R.sub.2 and R.sub.3 together constitute ##STR3## and R.sub.5 and R.sub.6 are hydrogen or optionally substituted phenyl, or a pharmacologically acceptable salt thereof, has platelet aggregation inhibitory activity and/or cyclic AMP/phosphodiesterase inhibitory activity.

6-substituted alkoxy-2-oxo-1,2-dihydroquinoxaline derivatives

Antibiotic neplanocin A of the formula ##STR1## is produced by culturing Ampullariella sp. A 11079 FERM-P No. 4494 in a nutrient medium and then separating the neplanocin A thus produced from the culture medium.

Antibiotic neplanocin A

Neplanocin-B and -F of the formula ##STR1## in which Y is oxygen or a valence bond, are produced by culturing Ampullariella sp. A 11079 FERM-P No. 4494 in a nutrient medium and then separating the neplanocin-B and -F thus produced from the culture medium.

Neplanocin-B and -F

A novel microorganism species belonging to the genus Micromonospora, i.e. Micromonospora sp. A 11725 is found to be capable of producing novel macrolide antibiotics A 11725 I, A 11725 II and A 11725 III. Novel antibiotics A 11725 Ia and A 11725 IIa are also found to be derived by chemical modification of the antibiotics A 11725 I and A 11725 II, respectively. All of these antibiotics or salts thereof exhibit excellent antibacterial and anti-mycoplasmal activities against various microorganisms such as Staphylococcus or Mycoplasma, and therefore useful for various purposes including medicaments.

Novel macrolide antibiotics and preparation thereof

An amino sugar compound represented by the general formula: ##STR1## (wherein m is an integer of 0 to 8, n is an integer of 1 to 8 and m+n is an integer of 1 to 8) has strong glycosidase inhibiting action and is produced by culturing an amino sugar compound producing microorganisms belonging to Streptomyces.

Amino sugar compound

A family of antibiotics active against pathogenic yeasts and fungi comprises aculeacin-A, -B, -C, -D, -E, -F, and -G. These are produced from cultured broth of Aspergillus aculeatus FERM-P 2324.

Antibiotic aculeacins

Growing community of inventors

Shizuoka, Japan

Tetsu Saito